Emerging therapeutic targets for glioblastoma multiform

Bibliography

• VALTONEN S, TIMONEN U, TOIVANEN P et al.: Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery (1997) 41:44–49.
   PubMed Web of Science ®Google Scholar
• BURTON E, PRADOS M: New chemotherapy options for the treatment of malignant gliomas. Curr. Opin. Oncol (1999) 11:157–161.
   PubMed Web of Science ®Google Scholar
• SUBACH BR, WITHAM TF, KONDZIOLKA D et al.: Morbidity and survival after 1,3-bis(2-chloroethy1)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery (1999) 45:17–22.
   PubMed Web of Science ®Google Scholar
• HO S-Y, BARBARESE E, D'ARRIGO JS et al: Evaluation of lipid-coated microbubbles as a delivery vehicle for taxol in brain tumour therapy. Neurosurgery (1997) 40:1260–1268.
   PubMedGoogle Scholar
• KAKINUMA K, TANAKA R, TAKAHASHI H et.al.: Targeting chemotherapy for malignant brain tumours using thermosensitive liposome and localized hypothermia. Neurosurg. (1996) 84:180–184.
   Google Scholar
• MCCAUGHAN JS: Photodynamic therapy. Drug Aging (1999) 15:49–68.
   PubMed Web of Science ®Google Scholar
• •A very good review of photodynamic therapy.
   Google Scholar
• BARTH RF, SOLOWAY AH, GOODMAN JH et al.: Boron neutron capture therapy of brain tumours: an emerging therapeutic modality. Neurosurgery (1999) 44:433–451.
   PubMed Web of Science ®Google Scholar
• JOHANNESEN TB, WATNE K, LOTE K et al.: Intracavity fractionated balloon brachytherapy in glioblastoma. Acta Neurochir. (Wien) (1999) 141:127–133.
   PubMedGoogle Scholar
• ZHANG W, LAW RE, HINTON DR et al.: Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor. Cancer Lett. (1997) 120:31–38.
   PubMed Web of Science ®Google Scholar
• SHAWVER LK, SCHWARTZ DP, MANN E et al: Inhibition of platelet-derived growth factor-mediated signal transduction and tumour growth by Is144-(trifluoro-methyl) -p heny115 -methylis oxazole-4 -carboxamide Clin. Cancer Res. (1997) 3:1167–1177.
   Google Scholar
• PENAR PL, KHOSHYOMM S, BHUSHAN A et.al.: Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery (1997) 40:141–151.
   PubMed Web of Science ®Google Scholar
• WEIL RJ, WU YY, VORTMEYER AO et al.: Telomerase activity in microdissected human gliomas. Mod. Pathol. (1999) 12(1):41–46.
   PubMedGoogle Scholar
• JOE YA, HONG YK, CHUNG DS et al: Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3. Int. J. Cancer (1999) 82:694–699.
   PubMedGoogle Scholar
• CUEVAS P, CARCELLER F, REIMERS D et al.: Inhibition of intra-tumoural angiogenesis and glioma growth by the fibroblastgrowthfactorinhibitor1,3,6-naphthalenetrisulfonate. Neurol. Res. (1999) 21:481–487.
   PubMed Web of Science ®Google Scholar
• BERNSEN HJJA, RIJKEN PFJW, PETERS JPW et al.: Delayed vascular changes after antiangiogenic therapy with antivascular endothelial growth factor antibodies in human glioma xenografts in nude mice. Neurosurgery (1998) 43:570–576.
   PubMedGoogle Scholar
• SILLS AK, JR., WILLIAMS JI, TYLER BM et al: Squalamine inhibits angiogenesis and solid tumour growth in vivo and perturbs embryonic vasculature. Cancer Res. (1998) 58:2784–9272.
   PubMed Web of Science ®Google Scholar
• PURI RK: Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma. Toxicol Pathol. (1999) 27:53–57.
   PubMed Web of Science ®Google Scholar
• MARUNO M, YOSHIMINE T, ISAKA T et al.: Cellular targets of exogenous tumour necrosis factor-alpha (INFO in human gliomas. Acta Neurochir. (Wien) (1996) 138:1437–1441.
   PubMedGoogle Scholar
• DEBINSKI W, GIBO DM, OBIRI NI et al: Novel anti-brain tumour cytotoxins specific for cancer cells. Nature Biotechnol. (1998) 16:449–453.
   PubMed Web of Science ®Google Scholar
• LASKE DW, YOULE RJ, OLDFIELD EH: Tumour regres-sion with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumours. Nature Med. (1997) 3:1362–1368.
   PubMed Web of Science ®Google Scholar
• JEAN WC, SPELLMAN SR, WALLENFRIEDMAN MA: Interleukin-12-based immunotherapy against rat 9L glioma. Neurosurgery (1998) 42:850–857.
   PubMed Web of Science ®Google Scholar
• WALLENFRIEDMAN MA, CONRAD JA, DELABARRE L et al: Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumour regression. J. Neurosurg. (1999) 90:1064–1071.
   PubMed Web of Science ®Google Scholar
• LIAU LM, BLACK KL, PRINS RM et al.: Treatment of intrac-ranial gliomas with bone marrow-derived dendritic cells pulsed with tumour antigens. J. Neurosurg. (1999) 90:1115–1124.
   PubMed Web of Science ®Google Scholar
• SALAZAR AM, LEVY HB, ONDRA S et al.: Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellu-lose: an open pilot study. Neurosurgery (1996) 38:1096–1104.
   PubMed Web of Science ®Google Scholar
• ULLYATT E, LIANG BC: 2',3'-Dideoxycytidine is a potent inducer of apoptosis in glioblastoma cells. AntiCancer Res. (1998) 18(3A):1859–1863.
   PubMedGoogle Scholar
• Textbook of Gene Therapy. Jam KK (Ed.), Hogrefe & Huber, Gottingen-Seattle (1998).
   Google Scholar
• ••Review of techniques of gene therapy with a chapter ongene therapy of brain tumours.
   Google Scholar
• KONDO S, ISHIZAKA Y, OKADA T et al: FADD gene therapy for malignant gliomas in vitro and in vivo. Hum. Gene Ther. (1998) 9:1599–1608.
   PubMedGoogle Scholar
• MACHEIN MR, RISAU W, PLATE KH: Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Hum. Gene Ther. (1999) 10:1117–1128.
   PubMed Web of Science ®Google Scholar
• PALU G, CAVAGGIONI A, CALVI P et.al.: Gene therapy of glioblastoma multiform via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther. (1999) 6:330–337.
   PubMed Web of Science ®Google Scholar
• VANDIER D, RIXE O, BRENNER M et al.: Selective killing of glioma cell lines using an astrocyte-specific expres-sion of the herpes simplex virus-thymidine kinase gene. Can. Res. (1998) 58:4577–4580.
   PubMed Web of Science ®Google Scholar
• LANG FF, YUNG WKA, RAJU U et al.: Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene. J. Neurosurg. (1998) 89:125–132.
   PubMed Web of Science ®Google Scholar
• RAINOV NG, IKEDA K, QURESHI NH et al.: Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. Hum. Gene Ther. (1998) 10:311–318.
   Google Scholar
• MANOME Y, KUNIEDA T, WEN PY et al.: Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum. Gene Ther. (1998) 9:1409–1417.
   PubMed Web of Science ®Google Scholar
• FUEYO J, GOMEZ-MANZANO C, YUNG WKA et al.: Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology (1998) 50:1307–1315.
   PubMed Web of Science ®Google Scholar
• AMBAR BB, FREI K, MALPIERO U et al.: Treatment of glioma by administration of adenoviral vectors expressing Fas ligand. Hum. Gene Ther. (1999) 10:1641–1648.
   PubMed Web of Science ®Google Scholar
• ROGULSKI KR, KIM JH, KIM SH et al.: Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Ther. (1997) 8:73–85.
   PubMed Web of Science ®Google Scholar
• WANG ZH, ZAGZAG D, ZENG B et.al.: In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-alpha. J. Neuropathol. Exp. Neurol (1999) 58:847–858.
   PubMedGoogle Scholar
• PAULUS W, BAUR I, OBERER DM et.al.: Regulated expres-sion of the diphtheria toxin A gene in human glioma cells using prokaryotic transcriptional control elements. J. Neurosurg. (1997) 87:89–95.
   PubMed Web of Science ®Google Scholar
• HESDORFFER C, AYELLO J, WARD M et al.: Phase I Trial of Retroviral-Mediated Transfer of the Human MDR1 Gene as Marrow Chemoprotection in Patients Undergoing High-Dose Chemotherapy and Autolo-gous Stem-Cell Transplantation. J. Clin. Oncol. (1998) 16:165–172.
   PubMed Web of Science ®Google Scholar
• OKADA H, GIEZEMAN-SMITS KM, TAHARA H et al: Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumour vaccine. Gene Ther. (1999) 6(2)219–226.
   PubMedGoogle Scholar
• SHEVELEV A, BURFEIND P, SCHULZE E et al: Potential triple helix-mediated inhibition of IGF-I gene expres-sion significantly reduces tumorigenicity of glioblas-toma in an animal model. Cancer Gene Ther. (1997) 4:105–112.
   PubMedGoogle Scholar
• WALLENFRIEDMAN MA, CONRAD JA, CHIANG L et al: Antisense oligonucleotides to insulin-like growth Factor I receptor mediate a systemic defense against C6 rat glioma tumours. J. Neurosurg. (1996) 84:370A.
   Google Scholar
• SIOUD M, SORENSEN D. A nuclease resistant protein kinase Ca ribozyme blocks glioma cell growth. Nature Biotechnol. (1998) 16:556–562.
   PubMed Web of Science ®Google Scholar
• IM SA, GOMEZ-MANZANO C, FUEYO J et al.: Antiangio-genesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumour growth in vivo. Cancer Res. (1999) 59:895–900.
   PubMed Web of Science ®Google Scholar
• AGGARWAL BB, SCHWARZ L, HOGAN ME et al: Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells. Cancer Res. (1996) 56:5156–5164.
   PubMedGoogle Scholar
• YAZAKI T, AHMAD S, CHAHLAVI A et al: Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol. Pharmacol. (1996) 50:236–242.
   PubMed Web of Science ®Google Scholar
• KONDO S, KONDO Y, LI G et al: Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene (1998) 16:3323–3330.
   PubMed Web of Science ®Google Scholar
• BROADDUS WC, CHEN ZJ, PRABHU SS et.al.: Antiprolif-erative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells. Neurosurgery (1997) 41:908–915.
   PubMedGoogle Scholar
• LIAU LM, FAKHRAI H, BLACK KL: Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene. Neurol. Res. (1999) 20:742–747.
   Google Scholar
• WEYERBROCK A, OLDFIELD EH: Gene transfer technologies for malignant gliomas. Curr. Opin. Oncol (1999) 11:168–173.
   PubMedGoogle Scholar
• ••Excellent review of current and proposed gene therapyapproaches.
   Google Scholar
• KAPLAN RS. Complexities, pitfalls, and strategies for evaluating brain tumour therapies. Curr. Opin. Oncol (1998) 10:175–178.
   PubMedGoogle Scholar
• ••Review of problems of clinical trials to evaluate braintumour therapies.
   Google Scholar